Roche Holding AG (FRA:RHO) Unearned Premiums

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RHO Roche Holding AG FRA:RHO
74 GF Score
Price €377.80
GF Value €289.58
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roche Holding AG Unearned Premiums?

Unearned Premiums only applies to insurance companies.

FRA:RHO
74GF Score
Roche Holding AG FRA:RHO
Unearned Premiums is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Roche Holding AG (FRA:RHO) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of €377.80 is trading 30.5% above its estimated GF Value™ of €289.58. GuruFocus considers Roche Holding AG to be Modestly Overvalued.

Key valuation signals for FRA:RHO:

  • Unearned Premiums:
  • GF Value™: €289.58 vs. price of €377.80 (30.5% above fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the FRA:RHO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
74GF Score

Get the complete analysis for FRA:RHO

Unearned Premiums is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€377.80
Price
€289.58
GF Value